Please login to the form below
Simponi
This page shows the latest Simponi news and features for those working in and with pharma, biotech and healthcare.
Latest news
-
Takeda makes Crohn’s disease case for subcutaneous Entyvio
to compete strongly against well-established ulcerative colitis drugs such as Humira and Johnson &Johnson’s Simponi (golimumab).
-
Remicade safe from biosimilar competition this year, says J&J
Regardless, Caruso said that J&J's immunology franchise remains strong thanks to newer entrants such as Stelara (ustekinumab) and Simponi (golimumab) and with 10 new products filed with blockbuster potential ... Simponi grew 30% to $390m in the quarter,
-
NICE set to recommend seven biologics for severe rheumatoid arthritis
NICE's other new final draft recommendations for severe RA also include AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB Pharma's Cimzia (certolizumab pegol), Merck Sharp &Dohme's Simponi
-
NICE turns down Celgene's Otezla once again
infliximab), AbbVie's Humira (adalimumab) and Johnson &Johnson's Simponi (golimumab).
-
AbbVie remains top of immunology sales
J&J saw strong growth from its broad immunological drug range that includes Remicade (infliximab) and Simponi (golimumab), which both treat rheumatoid arthritis as well as other auto-inflammatory disorders, and
More from news
Approximately 6 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Biosimilars - the same, but different?
The two infliximab biosimilars are also included in the cost-effectiveness watchdog's ongoing appraisals of TNF-alpha inhibitors for ankylosing spondylitis and its review of Humira, Enbrel, Remicade, Cimzia, Simponi,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Active Life Ahead: MSD, Simponi - Brand Campaign
44 7595 003744. Address:. Greencoat House. Francis Street. London. SW1P 1DH. United Kingdom.
-
Active Life Ahead: Press Advert
Client: Merck Sharp &Dohme. Therapy area: Musculo-skeletal Disorders. View the PMHub profile for: VCCP Health.
-
Brand leaders in RA will lose market share, predict rheumatologists
leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from biosimilar
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- New Omicron sub-variants cause COVID-19 cases to rise in the UK
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- First evidence-based guide launched to put patients at heart of digital innovations
- FDA grants Priority Review for Biogen and Eisai’s lecanemab for early Alzheimer’s disease
- New Swiss research reveals how Omicron evades the immune system
- Evoke Kyne Named Communiqué Communications Consultancy of the Year 2021
- Michael Grela Elected President of the Society for Health Communication
- Evoke Kyne Appoints Maureen Byrne to President and Promotes Four Executive Leaders
- Roche shares new positive Ocrevus data for MS patients
- A creative awakening – how pharma is bringing innovation to the patient journey
- European Commission approves potential new treatment for Pompe disease
- The importance of beliefs in creative health engagement
- Launch leaders’ blog part 1
- Launch leaders' blog part 2
PMHub
Page & Page and Partners
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...
Latest intelligence
- Five big changes in the healthcare comms landscape
- The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch...
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
